Clinico-pathological effect of lung cancer on survival

  • Noor Fahad Muhammed Kurdistan Medical Board of Oncology, Rizgary Teaching Hospital, Erbil, Iraq.
  • Jangi Shawkat Salai Kurdistan Medical Board of Oncology, Erbil, Iraq.

Abstract

Objectives This study aimed to evaluate the effect of age, grade, stage, smoking, histology, sex, PS, and treatment of lung cancer patients on survival.Methods The study included 185 lung cancer patients, which are collected from two regional cancer registries in Erbil City from Rizgary and Nanakaly General Hospital from January 2016 till December 2016 and followed up till October 2017. Patient information sheet involves all available demographic, diagnostic, chemotherapeutic, histological and disease state data.Results Most of the patients were diagnosed with lung cancer were after the age of 60 years old (91 patients, 60.66%). The most common histological types were non-squamous cell carcinoma (NSCLC) in 72 patients (84%). Patient’s survival was significantly higher in males comparing to females. About 13% of the male and 16% of the female were at PS3. Higher percentage of female patients was at grade III in comparison to the male. In addition to that, 75.86% of the female and 66.66% of the male was at stage IV of the disease. The survival period of the patients was significantly less at grade III in comparison to the patients at grade II in both squamous and NSCLC (p = 0.009, 0.0029 consequently). Likewise, the survival period of the patients was significantly less in advanced stage in comparison to the early stage in both squamous and NSCLC (p = 0.0035, 0.00058 consequently). The survival period of the patients was significantly less between patients with PS0 and PS3, in addition to that between PS1 and PS3 (p = 0.00583). A significant negative correlation was found between lung cancer patient survival and smoking history with r2 is equal to −0.038.Conclusion The survival period and rate is highly influenced by the factors such as age, sex, smoking, stage, grade and PS.
share this Article by

References

1. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30:93–98.
2. Molina JR1, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
3. Singh N, Behera D. Palliation in metastatic non-small cell lung cancer: Early integration with standard oncological care is the key. Lung India. 2014;31:317–319.
4. Redd WH, Montgomery GH, DuHamel KN. Behavioral Intervention for Cancer Treatment Side Effects. J Natl Cancer Inst. 2001;93:810–823
5. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010;116:659–669.
6. American Joint Committee on Cancer. “Lung Cancer Staging”. Available at: http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.
7. Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol. 2008;38:381–386.
8. Jemal A, Cokkinides VE, Shafey O, Thun MJ. Lung cancer trends in young adults: an early indicator of progress in tobacco control (United States). Cancer Causes Control. 2003;14:579–585.
9. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325–380.
10. Beadsmoore CJ, Screaton NJ. Classification, staging and prognosis of lung cancer. Eur J Radiol. 2003;45:8–17.
11. Mayo Clinic Staff. Cancer Survival Rate: What it Means for Your Prognosis. Mayo Clinic E-newsletters, 2018.
12. Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer (Auckl). 2012;3:79–89.
13. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results Database. Chest 2005;127:768–777.
14. Donaldson MS. Nutrition and cancer: a review of the evidence for an anticancer diet. Nutr J. 2004;3:19.
15. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016;11:1411–1422.
16. Noggle Space CA. Neuropsychology of Cancer and Oncology. Springer Publishing Company, 2012, p. 343 .
17. Torre LA1, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
18. Gordon T, Kannel WB. Drinking and mortality. The Framingham Study. Am J Epidemiol. 1984;120:97–107.
19. Prescott E, Grønbaek M, Becker U, Sørensen TI. Alcohol intake and the risk of lung cancer: influence of type of alcoholic beverage. Am J Epidemiol. 1999;149:463–470.
20. Gajra A, Marr AS, Ganti AK. Management of patients with lung cancer and poor performance status. J Natl Compr Canc Netw. 2014;12:1015–1025.
21. American cancer society. About Non-Small Cell Lung Cancer. 2014, p. 17.
Published
2018-09-15
How to Cite
MUHAMMED, Noor Fahad; SALAI, Jangi Shawkat. Clinico-pathological effect of lung cancer on survival. Iraq Medical Journal, [S.l.], v. 2, n. 3, p. 79-82, sep. 2018. ISSN 2521-8492. Available at: <http://www.jocms.org/index.php/imj/article/view/444>. Date accessed: 20 nov. 2018.
Section
Articles